Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Exploring the companies and themes that make up this emerging and exciting new sector
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
New 5-Year Psychedelics Warrants Offer Exciting Leverage Play
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
Countdown to Psychedelic Stock Rally, Part 2: Sector-Wide Catalysts
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
MINDCURE Announces Listing of Warrants
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
MindMed inks a new partnership for drug development and expands its pipeline.
264 Million Reasons Psychedelic Stocks Have More Room to Grow
There is big money to be made from psychedelic stocks and the companies planning to treat depression will be the winners.
Texas Would Study Psilocybin And MDMA To Treat PTSD And Depression Under New Bill
A Texas lawmaker introduced a bill on Wednesday that would require the state to study the therapeutic potential of psilocybin, MDMA and ketamine in the treatment of certain mental health conditions.
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
Iowa GOP Lawmaker Makes Another Push To Decriminalize Psilocybin Mushrooms
A Republican lawmaker in Iowa is taking another swing at reforming the state’s psychedelics laws, introducing a bill on Tuesday to remove psilocybin from the list of controlled substances.
Countdown to Psychedelic Stock Rally, Part 1: Individual Drivers
After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.